AgelessRx Research
AgelessRx PEARL Trial: Rapamycin & LDN Bone Density Findings
Explore PEARL trial findings on Rapamycin, Low Dose Naltrexone, and bone density, including a notable case report, potential mechanisms, safety considerations, and the need for…
What The AgelessRx Rapamycin Study Revealed About Bioavailability
Fat intake, gut microbiome composition, and enzyme activity may all influence Rapamycin absorption. See what our study revealed.
Understanding Our SF-36 Quality of Life Study
Curious about the SF-36 quality of life study? Discover what this validated health survey measures and what our longevity research found.
LDN and NAD+ for Long COVID Fatigue: AgelessRx Trial Findings
Low Dose Naltrexone and NAD+ were tested together for Long COVID fatigue in our trial. Learn what the results showed and why the combination worked.
Acarbose Longevity Research: AgelessRx Trial Data
Our Research Team tracked Acarbose as a longevity intervention in a pilot trial. See biomarker findings, glucose data, and tolerability results.
Microdosing GLP-1 for Longevity: What Our Trial Is Studying
Explore how Microdosing Semaglutide may support metabolic health, inflammation, and longevity, including what our GLP-1 trial is studying.
XPRIZE Healthspan Update: Inside AgelessRx’s Longevity Clinical Trial
AgelessRx shares early XPRIZE Healthspan semifinal results and what they suggest about the future of personalized longevity medicine.
Inside the AgelessRx XPRIZE Trial
AgelessRx is an XPRIZE Healthspan semifinalist! Learn more about the AgelessRx XPRIZE trial and what this means for the future of aging.
AgelessRx Named Semi-Finalist in $101M XPRIZE Healthspan Global Competition
AgelessRx is a Semi-Finalist in the landmark XPRIZE Healthspan competition, a milestone that may propel longevity solutions to the spotlight.